ArticleCancers2019
The PAK1-Stat3 Signaling Pathway Activates
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Ivermectin, a potential anticancer drug derived from an antiparasitic drug.Pharmacological research · 2021Pooled it
- Cytoskeletal dynamics in breast cancer: mechanistic insights and therapeutic opportunities.Journal of the National Cancer Center · 2026Review
- Article
- Evaluation of cytotoxic and cellular effects of zinc nanoparticles from Saccharum officinarum (Jaggery) extract on breast cancer cells.Scientific reports · 2026Article
- The interplay between p21-activated kinases and tumour-infiltrating dendritic cells and T cells and its implication in pancreatic cancer immunotherapy.Cell communication and signaling : CCS · 2026Review
- Biogenic synthesis of bioactive zinc nanoparticles from cyanobacterial Nostoc sp. MK-7 for biomedical applications.Discover nano · 2026Article
- Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells.PloS one · 2026Article
- The Biological Role of the Signal Transducer and Activator of Transcription 1 (STAT1)-miR-221/222-3p-p21 Activated Kinase 1 (PAK1) Axis in Experimental Periodontitis.Inflammation · 2025Article
- Therapeutic and Formulation Advances of Ivermectin in Veterinary and Human Medicine.Pharmaceutics · 2025Review
- Optimization of ultrasonic-assisted extraction of anthocyanins fromFood science and biotechnology · 2025Article
- Doramectin Induces Apoptosis in B16 Melanoma Cells.Anti-cancer agents in medicinal chemistry · 2025Article
- Therapeutic vulnerabilities of cancer stem cells and effects of natural products.Natural product reports · 2023Review
- LINC00467 induces melanoma deterioration by targeting miR-485-5p/p21 activated kinase 1.Journal of medical biochemistry · 2023Article
- Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures.International journal of molecular sciences · 2023Article
- Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity.Biomedicines · 2023Review
- A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?Inflammopharmacology · 2023Review
- PAK1 overexpression promotes myxofibrosarcoma angiogenesis through STAT5B-mediatedInternational journal of biological sciences · 2023Article
- Influence of Long Non-Coding RNA in the Regulation of Cancer Stem Cell Signaling Pathways.Cells · 2022Review
- Review
- [Blocking PAK1 kinase activity promotes the differentiation of acute megakaryocytic leukemia cells and induces their apoptosis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cancer stem cells (CSCs) have unique properties, including self-renewal, differentiation, and chemoresistance. In this study, we found that p21-activated kinase (PAK1) inhibitor (Group I, PAK inhibitor, IPA-3) and inactivator (ivermectin) treatments inhibit cell proliferation and that tumor growth of PAK1-knockout cells in a mouse model is significantly reduced. IPA-3 and ivermectin inhibit CSC formation. PAK1 physically interacts with Janus Kinase 2 (JAK2), and JAK2 inhibitor (TG101209) treatment inhibits mammosphere formation and reduces the nuclear PAK1 protein level. PAK1 interacts with signal transducer and activator of transcription 3 (Stat3), and PAK1 and Stat3 colocalize in the nucleus. We show through electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), and reporter assays that the PAK1/Stat3 complex binds to the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.